Cambrex Increases API Capacity in US, Europe
PTSM: Pharmaceutical Technology Sourcing and Management
Cambrex announces expansions of its North Carolina API pilot plant and Kalskoga, Sweden large-scale manufacturing facility.
Cambrex Corporation, a manufacturer of small molecule innovator and generic APIs, announced facility expansions in the United States and Europe.
On May 16, 2017, the company reported a $2.4 million investment to expand pilot plant capabilities at its High Point, NC facility, increasing the site's reactor capacity by 30%. The new 400-sq.-ft. suite-the site’s fourth reactor suite-will feature two 2000-L reactors and a 0.6-sq-meter Hastelloy filter dryer and is expected to be operational by early 2018.
In a second investment at the High Point site, the company plans to upgrade its analytical chromatography data systems for quality control and analytical R&D to Empower 3 software (Waters). in Q3 and Q4 of 2017.
On May 30, 2017, the company announced the expansion of large-scale manufacturing capacity and additional continuous-flow manufacturing capacity for high-purity intermediates at its cGMP facility in Karlskoga, Sweden.
The expansion includes the installation of multi-purpose reactors ranging from 4–12 cu. meters and upgrading of the control room within an existing plant on site. Installation of the new equipment, including a 9-cu. meter hydrogenation reactor, is expected to be completed by Q3 2017.
The company also introduced a dedicated continuous flow production unit, capable of producing multiple metric tons of high-purity intermediates per year.
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
